All News

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence.

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence.

Adding Avastin to standard therapy delays progression of advanced HER2-negative breast cancer in women without prior treatment.

A large phase III study examining whether the addition of Tarceva (erlotinib) to Avastin (bevacizumab) delayed progression of advanced non-small cell lung cancer reached its primary goal.

Results from an international study challenge current practice of screening for ovarian cancer relapse.

Researchers of a follicular lymphoma trial hope that BiovaxID, a personalized vaccine, could help delay recurrences.

The breast cancer drug Herceptin (trastuzumab) extends survival in certain gastric cancer patients by almost three months, according to a phase III international study.

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence.

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed.

Educational campaign launched to help nurses help patients who have treatment-related rash.

For 25 years, surgical and medical oncologists have gathered in sunny Miami to discuss the latest strategies in breast cancer management.